Study guide
2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide
2 Chapter 2: Cancer & Cancer Treatment Modalities
2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging
3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors
4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy
4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome
5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination
5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes
6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety
6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology
7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics
7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics
2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
Key Takeaways Explain This Topic AI
Autologous HSCT utilizes the patient's own harvested stem cells to restore hematopoiesis following high-dose chemotherapy, eliminating GVHD risk but carrying no Graft-versus-Tumor (GVT) effect.
Allogeneic HSCT utilizes donor stem cells (matched related, unrelated, or cord blood), providing a therapeutic GVT effect but carrying a substantial risk for Graft-versus-Host Disease (GVHD).
Myeloablative conditioning (MAC) regimens utilize high-dose total body irradiation (TBI) and alkylating agents, causing total bone marrow ablation, profound pancytopenia, severe Grade 3–4 mucositis, and sinusoidal obstruction syndrome (SOS).
Acute GI Graft-versus-Host Disease (aGVHD) targets intestinal crypt cells, staged by daily secretory diarrhea volume: Stage 1 (500–1,000 mL/day), Stage 2 (1,001–1,500 mL/day), Stage 3 (1,501–2,000 mL/day), and Stage 4 (>2,000 mL/day or severe ileus).
MNT for acute GI GVHD follows a structured step-up dietary reintroduction: Phase 1 complete bowel rest with TPN -> Phase 2 isotonic low-residue clear liquids -> Phase 3 low-fat soft foods -> Phase 4 regular diet as stoma/stool volume decreases below 500 mL/day.
Last updated: August 2026
2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
Hematopoietic Stem Cell Transplantation (HSCT) is an intensive, potentially curative procedure for hematologic malignancies (e.g., acute leukemias, aggressive lymphomas, multiple myeloma) and non-malignant hematologic disorders. HSCT involves eradication of the host immune system and malignant clones using high-dose conditioning therapy, followed by infusion of hematopoietic stem cells to re-establish blood cell production.
- Transplant Modalities & Stem Cell Sources
- 1. Autologous HSCT
Source: Patient's own hematopoietic stem cells harvested during clinical remission, cryopreserved, and re-infused following high-dose chemotherapy.
Clinical Purpose: Allows administration of supra-lethal doses of cytotoxic chemotherapy to eradicate residual malignant cells; stem cells serve solely as a rescue product to restore bone marrow function.
Immunological Features: Zero risk of Graft-versus-Host Disease (GVHD) ; however, there is no Graft-versus-Tumor (GVT) effect , carrying a higher relapse risk compared to allogeneic transplant.
2. Allogeneic HSCT
Source: Hematopoietic stem cells harvested from a Human Leukocyte Antigen (HLA)-matched donor—either a Matched Related Donor (MRD; e.g., sibling), Matched Unrelated Donor (MUD), or Haploidentical donor (50% match; parent/child).
Clinical Purpose: Eradicates host marrow and establishes a new donor immune system.
Immunological Features: Donor T-cells recognize residual recipient tumor cells as foreign, exerting a beneficial Graft-versus-Tumor (GVT) effect . However, donor T-cells also attack normal recipient host tissues, causing Graft-versus-Host Disease (GVHD) .
3. Umbilical Cord Blood (UCB)
Source: Stem cells collected from newborn placenta/umbilical cord blood.
Features: Less strict HLA-matching requirements due to immunologically naive T-cells; however, low total cell dose results in delayed engraftment and prolonged neutropenia.
Conditioning Regimens
Conditioning is administered prior to stem cell infusion (Days -7 to -1) to eradicate malignant cells, create space in bone marrow niches, and suppress host immunity to prevent graft rejection.
Conditioning Type Regimen Characteristics Primary Toxicities & Clinical Impact
Myeloablative Conditioning (MAC) High-dose Total Body Irradiation (TBI) + high-dose chemotherapy (e.g., Busulfan + Cyclophosphamide). Causes irreversible bone marrow destruction; engraftment is mandatory for survival. Severe Grade 3–4 Mucositis: Total GI mucosal denudation from mouth to anus.; Sinusoidal Obstruction Syndrome (SOS / VOD): Hepatic veno-occlusive disease caused by endothelial injury in liver sinusoids, manifesting as painful hepatomegaly, jaundice, and ascites.; Profound Anorexia & Nausea.
Reduced-Intensity / Non-Myeloablative (RIC / NMA) Lower doses of chemotherapy (e.g., Fludarabine + Melphalan) without total marrow ablation. Relies primarily on the donor GVT effect to eradicate malignancy. Lower immediate mucosal toxicity; suitable for older adults (>65 years) or patients with significant pre-existing comorbidities.
Graft-versus-Host Disease (GVHD)
GVHD is a major cause of morbidity and mortality following allogeneic HSCT. It is mediated by donor T-lymphocytes that recognize histocompatibility antigens on recipient target tissues as foreign.
1. Acute GVHD (aGVHD)
Onset: Historically defined as occurring within 100 days post-transplant (classic aGVHD).
Primary Target Organs: Skin (maculopapular rash), Liver (cholestatic jaundice, elevated bilirubin), and Gastrointestinal Tract (secretory diarrhea, mucosal sloughing, severe abdominal cramps, ileus). +---------------------------------------------------------------------------------------------------------+
- | ACUTE GI GVHD STAGING (BY DIARRHEA VOLUME) |
- | Stage 1: Diarrhea volume 500 - 1,000 mL/day (or 10-15 mL/kg/day in pediatrics). |
- | Stage 2: Diarrhea volume 1,001 - 1,500 mL/day (or 16-20 mL/kg/day). |
- | Stage 3: Diarrhea volume 1,501 - 2,000 mL/day (or 21-25 mL/kg/day). |
- | Stage 4: Diarrhea volume >2,000 mL/day (or >25 mL/kg/day), OR severe abdominal pain, ileus, bloody stool.|
- +---------------------------------------------------------------------------------------------------------+
- 2. Chronic GVHD (cGVHD)
Onset: Typically occurs >100 days post-transplant, resembling autoimmune disorders (e.g., systemic sclerosis, Sjögren's syndrome).
Clinical Manifestations: Sclerodermatous skin changes, oral sicca syndrome (dry mouth, mucosal lichenoid lesions), esophageal web/stricture formation, bronchiolitis obliterans (lung damage), chronic cholestatic liver disease, and widespread malabsorption.
- Nutritional Management Across HSCT Phases
- Phase I: Hyperacute & Engraftment Phase (Days 0 to +30)
Clinical Status: Profound neutropenia (ANC <500/mcL), severe Grade 3–4 mucositis, intractable nausea, vomiting, and diarrhea.
MNT Interventions:
Parenteral Nutrition (PN) Indication: Standard indication when oral intake is anticipated to be <50–60% of estimated energy/protein requirements for >7–10 days due to severe mucositis or gut toxicity.
PN Prescription: Central line administration; non-protein calories provided as dextrose and IV lipid emulsion; protein provision 1.5–2.0 g/kg body weight/day to offset severe catabolism.
Food Safety / Infection Control: Rigorous safe food handling guidelines (avoiding raw or undercooked meats, unpasteurized dairy, unwashed fruits/vegetables) to minimize neutropenic infection risks.
Phase II: Acute GI GVHD Management (Gut Rest & Trophic Feeding)
When acute GI GVHD presents with massive secretory diarrhea (>1.5–2.0 L/day), severe abdominal cramping, or ileus, aggressive nutritional staging is essential to allow mucosal healing. +---------------------------------------------------------------------------------------------------------+
- | 4-PHASE DIETARY REINTRODUCTION PROTOCOL |
- | Phase 1 (Gut Rest): Complete NPO with Total Parenteral Nutrition (TPN) during severe diarrhea |
- | (>1,000-1,500 mL/day) and abdominal pain. |
- | Phase 2 (Trophic Feed): Initiate isotonic, lactose-free, low-fat, low-residue clear liquids |
- | (e.g., oral rehydration solutions, diluted elemental formulas) when diarrhea |
- | decreases to <1,000 mL/day. |
- | Phase 3 (Soft Diet): Introduce low-fat (<20-30g/day), low-fiber, lactose-free, non-irritating soft |
- | solids as diarrhea stabilizes at <500 mL/day. |
- | Phase 4 (Regular): Gradual reintroduction of healthy fat, fiber, and intact milk protein as |
- | immunosuppressive steroids are tapered and gut function normalizes. |
- +---------------------------------------------------------------------------------------------------------+
- Phase III: Chronic GVHD & Long-Term Recovery
Steroid-Induced Osteoporosis: High-dose systemic corticosteroid therapy (e.g., prednisone) causes severe bone loss and osteonecrosis.
MNT: Supplemental Calcium (1,200 mg/day) and Vitamin D (1,000–2,000 IU/day) ; routine DEXA bone density screening.
Oral Sicca & Dysphagia: Artificial saliva, high-calorie liquid nutrition supplements.
Immunosuppression Maintenance: Continued vigilance with food safety and nutritional monitoring until all immunosuppressive agents are discontinued.